A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia

•A QSR was carried out to define the clinical, economic, and quality of life outcomes for ESAs in patients with CKD-induced anemia or CIA.•The evidence suggests little difference in efficacy, quality of life, and safety outcomes among ESA types.•Cost-effectiveness and downward pressure on market price are likely to become the main factors driving the choice of agent.